Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Pfizer RA Drug Meets Study Goals

April 29, 2011 6:43 am | News | Comments

Drug developer Pfizer Inc. said that its potential rheumatoid arthritis drug met key treatment goals in two late-stage studies. The drug candidate tofacitinib, formerly called tasocitinib, met its key goals of reducing signs and symptoms of the condition.


Pfizer Maintains Dividend, Directors Re-elected

April 29, 2011 6:41 am | News | Comments

Pfizer Inc. said shareholders at its annual meeting voted in favor of its nominees to its board and for a proposed executive compensation package. Pfizer, the world's largest drugmaker, also said it is maintaining its quarterly dividend of 20 cents.


Cheaper Eye Drug As Good As Pricier One

April 29, 2011 6:38 am | by Marilynn Marchione | News | Comments

A much cheaper drug has proved just as good as a $2,000 monthly shot at treating a common eye disorder that can lead to blindness, a long-awaited study has found. It also shows that patients can be treated less often, sparing them a lot of pain and expense.


HGS Hurt By Drug Costs

April 29, 2011 6:35 am | News | Comments

Human Genome Sciences Inc. reported a larger first-quarter loss as it booked bigger costs due to licensing an experimental cancer drug and launching its newly-approved lupus drug Benlysta.


Merck Profits Triple in 1Q

April 29, 2011 6:31 am | by Linda A. Johnson | News | Comments

Merck & Co. said its first-quarter profit more than tripled as strong sales of key drugs and lower costs from integrating its Schering-Plough acquisition offset sales lost to competition from generic versions of its drugs.


EU Probes Teva, Cephalon Deal on Sleeping Drug

April 29, 2011 6:29 am | News | Comments

European Union antitrust regulators said they are investigating whether drug makers Cephalon and Teva were working to keep a generic version of sleep-disorder drug Provigil out of the European market.


Allergan Hit with $212M Verdict

April 29, 2011 6:27 am | by Larry O'Dell | News | Comments

A federal jury awarded $212 million to a Virginia man who claimed injections of the wrinkle-smoothing drug Botox to treat hand tremors and writer's cramp left him brain-damaged and disabled.


Combination Testing System

April 28, 2011 8:23 am | Product Releases | Comments

MOCON, Inc. is introducing the MultiCheck 400, a first-of-its-kind combination testing system for packages with one-way degassing valves. The system measures oxygen headspace, leak detection, and seal strength.


Double-Quenched Probe

April 28, 2011 8:19 am | Product Releases | Comments

Integrated DNA Technologies offers its double-quenched probe, to increase the accuracy and reliability of 5’ nuclease qPCR experiments. This design positions an internal ZEN quencher 9 bases from the 5’ fluorophore, which increases sensitivity.


Pain Therapeutics Shrinks Q1 Loss

April 28, 2011 8:08 am | News | Comments

Pain Therapeutics Inc. on reported a smaller first-quarter loss on lower costs as the company awaits a regulatory decision on the painkiller Remoxy.


Novo Nordisk 1Q Profit Up 23%

April 28, 2011 8:06 am | News | Comments

Danish pharmaceutical company Novo Nordisk A/S says first-quarter net profit grew 23 percent to 4.07 billion kroner on strong sales. The world's biggest insulin maker says net profit in the January-March period grew from 3.3 billion kroner a year earlier.


New Method Extends Cancer-fighting Cells' Potency

April 28, 2011 8:04 am | News | Comments

White blood cells trained by scientists to attack tumors tend to fade away quickly when injected into cancer patients. A new technique, however, can allow the cells to survive in patients' bloodstreams for well over a year.


Researchers Use Collection of Approved Drugs to ID New Therapies

April 28, 2011 8:01 am | News | Comments

Researchers have begun screening the first definitive collection of thousands of approved drugs for clinical use against rare and neglected diseases. They are hunting for additional uses of the drugs hoping to find off-label therapies.


Vyvanse Performs Well in Phase 2 Trial

April 28, 2011 7:51 am | News | Comments

Shire plc announced positive results from a signal-finding study of Vyvanse Capsules assessing its effect in a prospective examination of adults with negative symptom predominant schizophrenia.


FDA Panel Backs Hepatitis Drug

April 28, 2011 7:46 am | by Matthew Perrone | News | Comments

The first new drug to treat hepatitis C in over 20 years moved one step closer to approval when a panel of government experts endorsed Merck's boceprevir as an effective treatment for the virus.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.